title: [Treatment of peritoneal carcinomatosis with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy].
abstract: Pinto Peritoneal carcinomatosis (PC) had for long been regarded as a terminal disease, characterized by a very poor survival and worthy of being treated with palliative therapy only. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) provide a promising additional treatment option for patients with peritoneal carcinomatosis, resulting in recently published series enable to obtain long-term survival. In spite of the need for more high quality studies, there is now a consensus among many international experts about the use of this new strategy as gold standard for treating with intent of cure selected patients with PC. We summarized the present status and possible future progress of this treatment modality, in particular outlining its rationale, current practice and general outcomes.
authors.affiliation: Universita degli Studi Siena, Policlinico Le Scotte, Dipartimento di Patologia Umana e Oncologia.
authors.forename: F
authors.initials: F
authors.lastname: Roviello
authors.forename: S
authors.initials: S
authors.lastname: Caruso
authors.forename: D
authors.initials: D
authors.lastname: Marrelli
authors.forename: C
authors.initials: C
authors.lastname: Pedrazzani
authors.forename: A
authors.initials: A
authors.lastname: Neri
authors.forename: A
authors.initials: A
authors.lastname: De Stefano
authors.forename: E
authors.initials: E
authors.lastname: Pinto
mesh_terms: D002277:Carcinoma / Q000188:drug therapy / Q000503:physiopathology / Q000601:surgery / Q000628:therapy*; D010478:Chemotherapy, Cancer, Regional Perfusion; D003131:Combined Modality Therapy; D006801:Humans; D006979:Hyperthermia, Induced; D010534:Peritoneal Neoplasms / Q000188:drug therapy / Q000503:physiopathology / Q000601:surgery / Q000628:therapy*; D011379:Prognosis